Venn provides Drug Development through its wholly owned subsidiary Kinesis Pharma BV.
Venn Life Sciences is a full service European Contract Research Organisation providing services and resourcing solutions to pharmaceutical, biotechnology and medical device companies.
With dedicated operations in France, Germany, the Netherlands, the UK, Ireland, and recently extending to the USA. Venn specialises in European-wide Phase I–Phase IV multi-site trials with extensive expertise in local regulations and local languages. Over 25 years, Venn Life Sciences has built up substantial study experience in a broad range of therapeutic areas, contributing to the efficient management of clinical trials with all parties involved.
In October 2015 Venn completed the acquisition of Kinesis Pharma BV, highly differentiating Venn within the CRO market as it can now offer integrated services from early development through to Phase IV development. This deepens its service capability and enables Venn to offer a complete end-to-end service.
Kinesis Pharma BV is a leading partner in early drug development which seamlessly integrates chemistry, manufacturing and control, non-clinical development, early clinical development, regulatory affairs, quality assurance and project management.